Covid19 Clinical Trial - Inspiratory Muscle Training in People With Long

Status Recruiting

Clinical Trial Summary

This pilot investigation will recruit people with Long COVID to participate in a 4 week individualized inspiratory muscle training intervention with pre and post spirometry testing and additional functional outcomes to assess the effectiveness of the intervention.

Clinical Trial Description

The study design is a 4 - week parallel-arm intervention, randomised controlled trial. Participants will attend 2 testing days, baseline and follow-up 4 weeks apart. Participants will first be screened over the phone to assess eligibility. Participants will then be randomly allocated using minimisation, into either control or intervention arm. Baseline testing: Participants will undergo baseline testing in the laboratory. Participants will be measured for their anthropometrics; height and weight. Participants will complete a series of questionnaires for 15 mins. Following 15 minutes rest, participants will then have three resting blood pressure and heart rate measurements and averaged via a sphygmomanometer and polar HR watch. MIP will be measured using the MicroRPM care fusion 3 times and the highest value reported (10 minutes). Forced expiratory value in 1 second (FEV1) and peak expiratory flow (PEF) will be measured using Vitalograph 700 (Spirotrac 6). Participants will undergo a 6-minute-walk-test self-paced where Rating of perceived exertion (RPE) and Borg dyspnea scale (BDS) will be assessed each minute. Then a sub-maximal exercise test using a cycle ergometer and VyntusCPX, where Ventilatory threshold (VT) and Maximal heart rate (HRMax)will be measured. Participants will be asked to cycle until they reach a 17 RPE on a ramp test of 10-15W/min (>20mins). Heart rate (HR), Rating percieved exertion (RPE) and Borg dyspnea scale BDS) measured each minute. The intervention arm will receive a handheld PrO2 device and will participate in two unsupervised sessions and one supervised via Microsoft teams sessions per week. Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6 x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day. The control group will be asked to continue as normal throughout the 4 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06091358
Study type	Interventional
Source	University of Bath
Contact	Rachel Eddy
Phone	00000000
Email	re415@bath.ac.uk
Status	Recruiting
Phase	N/A
Start date	October 20, 2023
Completion date	April 20, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05926505` - Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome	Phase 2/Phase 3
Recruiting	`NCT04872309` - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Completed	`NCT05552612` - Health-related Quality of Life and Long COVID
Completed	`NCT05531019` - COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A	N/A
Not yet recruiting	`NCT04949386` - Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.	Phase 2
Recruiting	`NCT06118112` - Living With Long COVID: LONGCOVID-EXPERIENCE
Completed	`NCT05185674` - Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
Enrolling by invitation	`NCT05965739` - RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms	N/A
Enrolling by invitation	`NCT05965752` - RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms	N/A
Completed	`NCT05812209` - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting	`NCT05606211` - Pain in Long COVID-19: The Role of Sleep
Active, not recruiting	`NCT05713266` - Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
Completed	`NCT05679505` - Vagus Nerve Stimulation for Post-COVID Syndrome	N/A
Completed	`NCT05601180` - Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.	N/A
Not yet recruiting	`NCT06045338` - Mind Body Intervention for Long COVID	N/A
Recruiting	`NCT05566392` - Longterm Influence of Pediatric Long COVID Syndrome
Recruiting	`NCT05855369` - Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss	Phase 2/Phase 3
Recruiting	`NCT05572346` - Digital App for Telerehabilitation in Respiratory Diseases
Recruiting	`NCT06316843` - Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2	Phase 2
Recruiting	`NCT06108297` - Lithium Long COVID Dose-finding Study	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms